Martin D. Madaus insider status at Haemonetics (NYSE: HAE) disclosed
Rhea-AI Filing Summary
Haemonetics Corp reported that Martin D. Madaus serves as a director and is now identified as a reporting person for the company’s equity securities. The insider data shows no reported transactions, with 0 shares bought or sold and no derivative positions listed.
Positive
- None.
Negative
- None.
Key Figures
Shares bought: 0 shares
Shares sold: 0 shares
Derivative transactions: 0 transactions
+1 more
4 metrics
Shares bought
0 shares
Buy transactions reported for Martin D. Madaus in this insider summary
Shares sold
0 shares
Sell transactions reported for Martin D. Madaus in this insider summary
Derivative transactions
0 transactions
Derivative transaction count in the transaction summary
Net buy/sell shares
0 shares
Net buy-sell position from the transaction summary (neutral direction)
Key Terms
reporting person, ten percent owner, derivative transactions
3 terms
reporting person regulatory
"ReportingPersons section lists Martin D. Madaus as a reporting person"
ten percent owner regulatory
"Field is_ten_percent_owner indicates ten percent owner status as 0"
derivative transactions financial
"transactionSummary shows derivativeTransactionCount for derivative transactions"
Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Haemonetics (HAE) Form 3 for Martin D. Madaus show?
It shows that Martin D. Madaus is a director and reporting person of Haemonetics. The insider summary lists 0 shares bought, 0 shares sold, and no derivative positions or holdings entries reported in this initial ownership statement.
Does Martin D. Madaus report any derivative positions in Haemonetics (HAE)?
No derivative positions are reported. The derivativeSummary is empty and the transaction summary lists 0 derivative transactions. This indicates no options, warrants, or other derivative securities are disclosed for Madaus in this particular insider statement.
Is Martin D. Madaus a ten percent owner of Haemonetics (HAE) according to this report?
No. The insider data flags is_ten_percent_owner = 0 for Martin D. Madaus. He is identified as a director but not as a ten percent owner, meaning he is not reported as holding at least ten percent of Haemonetics’ equity securities here.
Does the Haemonetics (HAE) Form 3 for Martin D. Madaus involve a Rule 10b5-1 plan?
There is no indication of a Rule 10b5-1 plan. The aff_10b5_one field is null, and there are no transaction footnotes describing trades under a pre-arranged trading plan, consistent with the absence of any reported buy or sell activity.